Medicine and Dentistry
Mesothelioma
100%
Estrogen Receptor Beta
83%
Neoplasm
50%
Patient
33%
Estrogen Receptor
33%
Prognostic Factor
33%
Tumor Suppressor Protein
33%
Analysis
16%
Combination Therapy
16%
Age
16%
Therapeutic Procedure
16%
Tissues
16%
P21
16%
Marker
16%
Survival
16%
Diagnosis
16%
Asbestos
16%
Incidence
16%
Female
16%
Disease Exacerbation
16%
Upregulation
16%
Malignant Neoplasm
16%
Motivation
16%
In Vitro
16%
Biological Product
16%
Cell Proliferation
16%
Pleura Mesothelioma
16%
down Regulation
16%
Cell Growth
16%
Multivariate Analysis
16%
Estradiol
16%
Gender
16%
Treatment Response
16%
Receptor Expression
16%
Cell Cycle Checkpoint
16%
Survivin
16%
Cell Cycle M Phase
16%
Estrogen Receptor Alpha
16%
Pharmacology, Toxicology and Pharmaceutical Science
Estrogen Receptor Alpha
16%